The treatment of SH-SY5Y JNK-KTR cells with either anisomycin (300 nM; 2 hours) or the neuroblastoma standard-of-care chemotherapy drug vincristine (300 nM; 4 hours) resulted in a broad distribution of single-cell responses, with no delayed activation apparent within cells that had low JNK activity at the peak time point. The gene discussed is MAPK8; the disease is neuroblastoma.